RT Book, Section A1 Held, Melissa A1 Cappello, Michael A2 Rudolph, Colin D. A2 Rudolph, Abraham M. A2 Lister, George E. A2 First, Lewis R. A2 Gershon, Anne A. SR Print(0) ID 7030800 T1 Chapter 323. Antiparasitic Therapy T2 Rudolph's Pediatrics, 22e YR 2011 FD 2011 PB The McGraw-Hill Companies PP New York, NY SN 978-0-07-149723-7 LK accesspediatrics.mhmedical.com/content.aspx?aid=7030800 RD 2024/03/28 AB Parasitic diseases afflict more than 2 billion people worldwide and are among the leading causes of death and chronic morbidity in resource-limited countries. Because parasites collectively represent a wide array of species, effective therapy of infections caused by these evolutionarily distinct eukaryotes requires an equally diverse armamentarium of pharmacologic agents. The past decade has seen a renewed commitment to antiparasitic drug development, spearheaded by novel public-private partnerships and supported by international philanthropic organizations, a commitment that may ultimately yield new agents for these globally important diseases.1-3 Equally encouraging is the recent recognition that integrated control of multiple tropical diseases can be achieved through periodic administration of inexpensive, orally available medicines to at-risk individuals living in endemic communities.4,5